Robin Guo
Chief Executive Officer Lionbio
Robin is the CEO of LionBio Therapeutics, a Columbia University spinout focused on commercializing various nanoparticle technologies. Before this, Robin was a partner at Andreessen Horowitz and founding team of a16z speedrun, the firm’s $1.2B pre-seed program. He began his career at McKinsey & Co. in the pharmaceuticals practice.
Seminars
Thursday 4th February 2027
Improving Bioavailability Through Smarter Formulation Design with Nanoparticles
12:00 pm
- Explore how nanoparticle-enabled delivery systems can overcome absorption barriers associated with peptides and biologics while minimizing systemic exposure
- Understand how intranasal GLP-1 delivery may create differentiated therapeutic profiles by targeting CNS pathways while potentially reducing gastrointestinal side effects
- Learn how developers are balancing bioavailability, manufacturability, safety, and scalability when advancing next-generation peptide therapies
